Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Spironolactone × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Other 1 Genitourinary 1

Conditions

Neoplasms 1 Critical Illness 1 Acute Kidney Injury 1

Interventions

Docetaxel 29 Radiosurgery 23 Radiotherapy 19 Sunitinib 18 Gemcitabine 15 Androgen Antagonists 15 Nivolumab 14 Cisplatin 14 Blood Specimen Collection 14 pembrolizumab 13 enzalutamide 12 Leuprolide 11 aldesleukin 10 Surveys and Questionnaires 10 Prednisone 10 bicalutamide 9 Goserelin 9 Cyclophosphamide 9 Carboplatin 9 Bevacizumab 9 Abiraterone Acetate 9 Multiparametric Magnetic Resonance Imaging 8 toripalimab 7 tislelizumab 7 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 7 Triptorelin Pamoate 7 Radiotherapy, Intensity-Modulated 7 Ipilimumab 7 Chemotherapy, Adjuvant 7 pazopanib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02531412 2017-01-04

SPIROCAN

Instituto Nacional de Cancerologia de Mexico

Phase 2/3 Unknown

Neoplasms, Critical Illness, Acute Kidney Injury

Data powered by HemOnc (CC BY 4.0) Colophon ⚡